BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

GlaxoSmithKline

Pfizer

GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines.

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) --  BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

MAINZ, Germany, April 7, 2024 -  BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neoantigen-specific immunotherapy (“iNeST”) candidate autogene cevumeran (also known as BNT122, RO7198457) in patients with resected pancreatic ductal adenocarcinoma (“PDAC”). The data show that in 8 out of 16 patients autogene cevumeran elicited an immune response up to three years post administration measured by activated T cells. The persistence of T cels was associated with a longer median recurrence-free survival in cancer vaccine responders.

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

JinkoSolar Holding

Vital Energy Inc

Best bargain stocks to buy is a simple but tricky concept. Whenever shares trade lower than an established multiple, whether that by earnings, sales, book or some other metric, there might be a reason for it.

The 3 Best Bargain Stocks to Buy in Q2 2024

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

As we step into March 2024, the spotlight is turning towards the biotech sector, with investors searching for biotech stocks to buy. Biotech stocks are ready to soar after a period of under-performance relative to the broader market.

3 Biotech Stocks to Buy for the Next Bull Run: March 2024

BioNTech said on Monday the U.S. National Institutes of Health has sent a notice to the German company regarding default on the payment of royalties and other amounts related to its COVID-19 vaccine.

BioNTech gets US agency notice over default on COVID vaccine royalties

BioNTech's Q4 earnings shows a significant revenue drop and profitability concerns, with expectations of continued vaccine demand decline. Despite short-term challenges, BioNTech's mRNA technology and pipeline, including COVID/flu vaccines and oncology, highlight long-term potential. Financials suggest a strong balance sheet, but projected R&D expenses indicate potential future cash burns.

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

BioNTech SE (BNTX) Q4 2023 Earnings Call Transcript

BioNTech stock tumbled Wednesday after the Covid vaccine maker reported light fourth-quarter sales and profit.

BioNTech Tumbles As Fourth-Quarter Sales Dive 65% And Miss Forecasts

The pharmaceutical firm has been hit hard as demand for Covid-19 vaccines plunged.

BioNTech Earnings Fall Short of Estimates. The Stock Is Down.

BioNTech SE (NASDAQ: BNTX) is down nearly 5.0% in premarket on Wednesday after reporting disappointing financial results for the fourth quarter. BioNTech stock down on muted guidance The stock is being hit because $BNTX did not issue an impressive guidance either.

BioNTech Q4 earnings: COVID franchise to remain a notable cash contributor in 2024

Shares of BioNTech SE BNTX, +1.22% dropped 4.4% in premarket trading Wednesday, after the Germany-based biotechnology company reported fourth-quarter results that fell sharply to miss expectations, weighed down by inventory writedowns by COVID-19 vaccine collaboration partner Pfizer Inc. PFE, -0.32% Net profit for the quarter to Dec. 31 dropped to EUR457.9 million ($496.5 million), or EUR1.90 a share, from EUR2.28 billion, or EUR9.26 a share, in the same period a year ago. That missed the FactSet consensus for earnings per share of EUR2.37.

BioNTech's stock sinks after earnings fall below expectations, hurt by writedowns of vaccine inventory

Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, reported on Wednesday a plunge in 2023 revenue and earnings as its focus shifts towards cancer drug development.

After earnings plunge, BioNTech pins hopes on cancer drug launches

Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024 Aiming for first oncology launch in 2026 and ten indication approvals by 2030 as part of BioNTech's strategy to develop combinatorial and synergistic therapeutic approaches Entered strategic coll aborations with Biotheus, DualityBio, Medilink and OncoC4 to complement clinical oncology pipeline with innovative antibody-drug conjugate (ADC) and immuno-modulatory programs Annemarie Hanekamp appointed as Chief Commercial Officer effective July 1, 2024 Delivered over 400 million COVID-19 vaccine doses worldwide in 2023, including successfully launched XBB.1.5 variant-adapted monovalent COVID-19 vaccine Progressed three infectious disease vaccine candidates into clinical evaluation, leveraging BioNTech's mRNA technology and expertise Fourth quarter and full year 2023 revenues of €1.5 billion and €3.8 billion, respectively Full year net profit of €0.9 billion and fully diluted earnings per share of €3.83 ($4.141) Strong financial position with €17.7 billion in cash, cash equivalents and security investments 2024 revenue guidance of €2.5 billion to €3.1 billion   Conference call and webcast scheduled for March 20, 2024, at 8:00 a.m. ET (1:00 p.m.

BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024. She will join BioNTech from Novartis AG (“Novartis”) and succeed Sean Marett in this role.

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

Immunocore Holdings

Vir Biotechnology

Since Bill Gates left his position with Microsoft (NASDAQ: MSFT ) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interest.

Billionaire's Biotech Bets: 3 Stocks Dominating Bill Gates' Portfolio

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=70683&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds BioNTech Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 12, 2024 - BNTX

NEW YORK , March 12, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, both dates inclusive (the "Class Period"), of the important March 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased BioNTech securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

BNTX DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=70600&wire=1 or contact Joseph E. Levi, Esq.

March 12, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BNTX

LOS ANGELES, CA / ACCESSWIRE / March 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioNTech SE ("BioNTech" or "the Company") (NASDAQ:BNTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 12, 2024.

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the Firm

NEW YORK , March 12, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioNTech investors who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023.

Class Action Filed Against BioNTech SE (BNTX) - March 12, 2024 Deadline to Join - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=70589&wire=1 or contact Joseph E. Levi, Esq.

BioNTech SE Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - BNTX

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=70538&wire=1 or contact Joseph E. Levi, Esq.

BioNTech SE Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BNTX

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=70569&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of BioNTech SE Should Contact Levi & Korsinsky Before March 12, 2024 to Discuss Your Rights - BNTX

NEW YORK, NY / ACCESSWIRE / March 11, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=70478&wire=1 or contact Joseph E. Levi, Esq.

News for BioNTech SE Stock (BNTX)